Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Tax Provisions (2016 - 2025)

Sangamo Therapeutics has reported Tax Provisions over the past 8 years, most recently at -$553000.0 for Q4 2025.

  • Quarterly results put Tax Provisions at -$553000.0 for Q4 2025, down 29.51% from a year ago — trailing twelve months through Dec 2025 was -$568000.0 (down 240.12% YoY), and the annual figure for FY2025 was -$568000.0, down 240.12%.
  • Tax Provisions for Q4 2025 was -$553000.0 at Sangamo Therapeutics, down from -$161000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for SGMO hit a ceiling of $1.3 million in Q3 2023 and a floor of -$6.3 million in Q2 2023.
  • Median Tax Provisions over the past 5 years was $78000.0 (2022), compared with a mean of -$250850.0.
  • Peak annual rise in Tax Provisions hit 4133.33% in 2023, while the deepest fall reached 7739.02% in 2023.
  • Sangamo Therapeutics' Tax Provisions stood at -$67000.0 in 2021, then surged by 486.57% to $259000.0 in 2022, then tumbled by 205.02% to -$272000.0 in 2023, then crashed by 56.99% to -$427000.0 in 2024, then dropped by 29.51% to -$553000.0 in 2025.
  • The last three reported values for Tax Provisions were -$553000.0 (Q4 2025), -$161000.0 (Q3 2025), and $27000.0 (Q2 2025) per Business Quant data.